Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03794128 · ClinicalTrials.gov registry record
A Study of Personalized Neoantigen Cancer Vaccines
A clinical trial, sponsored by Gritstone bio.
- Completed
- Registry status
- 93
- Enrollment target
NCT03794128 is a clinical trial that has completed, run by Gritstone bio. The registered enrollment target is 93 participants.
The verdict
NCT03794128 has completed, sponsored by Gritstone bio.
- COMPLETED
- Registry status
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted neoantigens; and, 2) to identify and select patients who may be eligible for a shared neoantigen cancer vaccine where their tumor contains a specific shared mutation and who have the correct HLA allele capable of presenting the neoantigen derived from the tumor-specific mutation.
Interventions
- PROCEDURE Blood collection for research (next-generation sequencing [NGS])
- PROCEDURE Blood collection for research (HLA typing)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2020-05-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03794128
The ClinicalTrials.gov registry entry for NCT03794128 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gritstone bio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood collection for research (next-generation sequencing [NGS]) is the first listed.
NCT03794128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03794128 about?
NCT03794128 is a clinical study titled "A Study of Personalized Neoantigen Cancer Vaccines". The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted neoantigens; and, 2) to identify and select patients who may be eligible ...
What is the current status of trial NCT03794128?
This trial is currently completed. The enrollment target is 93 participants. The study started on 2018-07-25. Estimated completion is 2020-05-26.
What interventions are being tested in trial NCT03794128?
The interventions under investigation include: Blood collection for research (next-generation sequencing [NGS]) (PROCEDURE), Blood collection for research (HLA typing) (PROCEDURE).
Who is sponsoring clinical trial NCT03794128?
This trial is sponsored by Gritstone bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.